Latest news

EMA grants Orphan Drug Designation to Debiopharm International SA’s IAP inhibitor Debio 1143 in the treatment of Ovarian Cancer

Debiopharm International SA’s partner Yakult Honsha Co, Ltd. announces Elplat® approbation in gastric cancer in Japan

Debiopharm International SA presents positive preliminary results from Phase 1 trials in the development of the IAP inhibitor Debio 1143…

The Japanese Cancer Association and Debiopharm Group Announce Winners of the 2015 JCA-Mauvernay Award

Debiopharm Group™ inaugure son site de production et son laboratoire de recherche après 18 mois de travaux, à Martigny.

Debiopharm International SA and Solid Biosciences, LLC, announce a collaboration to explore the use of Alisporivir (Debio 025) in muscular…

Debiopharm International SA acquires FibroTrap sample processing technology from Spinomix

Debiopharm International SA Announces Phase III Positive Results for Triptorelin 6-month Formulation in the Management of Central Precocious Puberty (CPP)

Debiopharm International SA initiates clinical phase II study evaluating Debio 1450 in Staphylococcal skin infections